Mads Krogsgaard on historical FDA approval: It will transform Novo Nordisk
The US approval of Novo Nordisk's diabetes tablet Rybelsus ensures the Danish drug group a future multi-blockbuster, says CSO Mads Krogsgaard Thomsen. However, he does not want to put exact figures on the tablet's economic potential.
In the end of March, Novo Nordisk filed for approval of its diabetes tablet and future growth driver Rybelsus – also known as oral semaglutide – with the US Food and Drug Administration (FDA).
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
